2025 Q4 -tulosraportti
Vain PDF
73 päivää sitten
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·5 t sittenHey everyone must wake up now approx 274600000 number of shares : 15923='each person approx 16226 number of impossible calculate out parts of lower 5,80kr I am study at stock school before it is max approx 7,30 kr cheaper now everyone must think how many calculate out of parts share themselves not noise and nonsense never everyone must relax now- ·10 t sittenCIRCIO – Are we at the beginning of something truly big? 🧬🚀 I think it's easy to forget how much has actually happened in Circio in recent months. For me, these are the most important triggers going forward: 🧬 Research on circRNA CircRNA is referred to as one of the most exciting technologies in next-generation gene and cell therapy. If Circio manages to document clear advantages, interest from larger pharmaceutical companies could increase significantly. 🤝 New research and partnership agreements The collaboration with Tcelltech shows that the technology is being taken seriously. I believe this could be the start of more agreements if the results are good. 💊 Preclinical results Good data can be what truly moves the company. In biotech, it is often the scientific results that create the biggest share price movements. 💰 Licensing agreements The truly significant value creation can come if Circio enters into licensing agreements with larger pharmaceutical companies. Then the company can receive milestone payments and later royalties without having to build a large sales organization themselves. 🌍 Increasing interest in RNA technology After the success with mRNA, more and more investors and pharmaceutical companies have opened their eyes to new RNA platforms. CircRNA could become an important part of the next wave of development if the technology delivers. 📈 The valuation If Circio succeeds in showing that the platform works as they hope, I believe today's market capitalization could look very modest. But this is still a development company, and the risk is high. Not all biotech projects succeed, and the path to commercial products can be long. Nevertheless, I find the relationship between potential upside and risk exciting. Therefore, I choose to be patient and follow the development closely. Not investment advice – just my own thoughts as a shareholder. 🧬📈💪
·10 t sittenNew technical analysis published: Double-crab formation is now consolidated. This means 82% probability that it continues to crawl downwards towards price 5.8 in the coming weeks. The technical analysis just shows that price 5.8 is hit on July 26 (uncertainty +/- 9 days) We know what we own 🦀💨💩
As I have said before, can't you rather spend your time on a new education at your fictional university? You know nothing about stock analysis, at least. I can say with 99% certainty that you are wrong, because this is just a number you throw out without any basis whatsoever, and the probability of hitting it is quite small.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
Vain PDF
73 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·5 t sittenHey everyone must wake up now approx 274600000 number of shares : 15923='each person approx 16226 number of impossible calculate out parts of lower 5,80kr I am study at stock school before it is max approx 7,30 kr cheaper now everyone must think how many calculate out of parts share themselves not noise and nonsense never everyone must relax now
- ·10 t sittenCIRCIO – Are we at the beginning of something truly big? 🧬🚀 I think it's easy to forget how much has actually happened in Circio in recent months. For me, these are the most important triggers going forward: 🧬 Research on circRNA CircRNA is referred to as one of the most exciting technologies in next-generation gene and cell therapy. If Circio manages to document clear advantages, interest from larger pharmaceutical companies could increase significantly. 🤝 New research and partnership agreements The collaboration with Tcelltech shows that the technology is being taken seriously. I believe this could be the start of more agreements if the results are good. 💊 Preclinical results Good data can be what truly moves the company. In biotech, it is often the scientific results that create the biggest share price movements. 💰 Licensing agreements The truly significant value creation can come if Circio enters into licensing agreements with larger pharmaceutical companies. Then the company can receive milestone payments and later royalties without having to build a large sales organization themselves. 🌍 Increasing interest in RNA technology After the success with mRNA, more and more investors and pharmaceutical companies have opened their eyes to new RNA platforms. CircRNA could become an important part of the next wave of development if the technology delivers. 📈 The valuation If Circio succeeds in showing that the platform works as they hope, I believe today's market capitalization could look very modest. But this is still a development company, and the risk is high. Not all biotech projects succeed, and the path to commercial products can be long. Nevertheless, I find the relationship between potential upside and risk exciting. Therefore, I choose to be patient and follow the development closely. Not investment advice – just my own thoughts as a shareholder. 🧬📈💪
- ·10 t sittenNew technical analysis published: Double-crab formation is now consolidated. This means 82% probability that it continues to crawl downwards towards price 5.8 in the coming weeks. The technical analysis just shows that price 5.8 is hit on July 26 (uncertainty +/- 9 days) We know what we own 🦀💨💩As I have said before, can't you rather spend your time on a new education at your fictional university? You know nothing about stock analysis, at least. I can say with 99% certainty that you are wrong, because this is just a number you throw out without any basis whatsoever, and the probability of hitting it is quite small.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
2025 Q4 -tulosraportti
Vain PDF
73 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·5 t sittenHey everyone must wake up now approx 274600000 number of shares : 15923='each person approx 16226 number of impossible calculate out parts of lower 5,80kr I am study at stock school before it is max approx 7,30 kr cheaper now everyone must think how many calculate out of parts share themselves not noise and nonsense never everyone must relax now
- ·10 t sittenCIRCIO – Are we at the beginning of something truly big? 🧬🚀 I think it's easy to forget how much has actually happened in Circio in recent months. For me, these are the most important triggers going forward: 🧬 Research on circRNA CircRNA is referred to as one of the most exciting technologies in next-generation gene and cell therapy. If Circio manages to document clear advantages, interest from larger pharmaceutical companies could increase significantly. 🤝 New research and partnership agreements The collaboration with Tcelltech shows that the technology is being taken seriously. I believe this could be the start of more agreements if the results are good. 💊 Preclinical results Good data can be what truly moves the company. In biotech, it is often the scientific results that create the biggest share price movements. 💰 Licensing agreements The truly significant value creation can come if Circio enters into licensing agreements with larger pharmaceutical companies. Then the company can receive milestone payments and later royalties without having to build a large sales organization themselves. 🌍 Increasing interest in RNA technology After the success with mRNA, more and more investors and pharmaceutical companies have opened their eyes to new RNA platforms. CircRNA could become an important part of the next wave of development if the technology delivers. 📈 The valuation If Circio succeeds in showing that the platform works as they hope, I believe today's market capitalization could look very modest. But this is still a development company, and the risk is high. Not all biotech projects succeed, and the path to commercial products can be long. Nevertheless, I find the relationship between potential upside and risk exciting. Therefore, I choose to be patient and follow the development closely. Not investment advice – just my own thoughts as a shareholder. 🧬📈💪
- ·10 t sittenNew technical analysis published: Double-crab formation is now consolidated. This means 82% probability that it continues to crawl downwards towards price 5.8 in the coming weeks. The technical analysis just shows that price 5.8 is hit on July 26 (uncertainty +/- 9 days) We know what we own 🦀💨💩As I have said before, can't you rather spend your time on a new education at your fictional university? You know nothing about stock analysis, at least. I can say with 99% certainty that you are wrong, because this is just a number you throw out without any basis whatsoever, and the probability of hitting it is quite small.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt